SEN54 Antibody

What is TSEN54 and what biological processes does it participate in?

TSEN54 (also known as SEN54) is a non-catalytic subunit of the tRNA-splicing endonuclease complex responsible for identification and cleavage of splice sites in pre-tRNA. This complex cleaves pre-tRNA at the 5' and 3' splice sites to release the intron, generating an intron and two tRNA half-molecules bearing 2',3' cyclic phosphate and 5'-OH termini. Notably, although there are no conserved sequences at the splice sites, the intron is invariably located at the same position, placing splice sites at a consistent distance from the structural features of the tRNA body .

Beyond its role in tRNA processing, TSEN54 is also involved in mRNA processing through its association with pre-mRNA 3'-end processing factors. This establishes an important link between pre-tRNA splicing and pre-mRNA 3'-end formation, suggesting that TSEN54 and other endonuclease subunits function in multiple RNA-processing events .

When conducting literature searches or designing experiments targeting TSEN54, researchers should be aware of the various aliases used to refer to this protein in scientific databases and publications:

• HsSEN54

• SEN54 homolog

• SEN54L

• tRNA-intron endonuclease Sen54

• tRNA-splicing endonuclease subunit Sen54

• PCH2A (associated with pontocerebellar hypoplasia type 2)

• PCH4 (associated with pontocerebellar hypoplasia type 4)

• PCH5 (associated with pontocerebellar hypoplasia type 5)

Awareness of these alternative designations is crucial for comprehensive literature searches and proper experimental design when working with TSEN54 antibodies.

How do I determine the optimal TSEN54 antibody for my specific research application?

Selection of the appropriate TSEN54 antibody depends on several factors including experimental technique, target species, and specific research question. For detecting TSEN54 in human samples, both monoclonal and polyclonal options are available. If high specificity is required (e.g., distinguishing between closely related proteins), a monoclonal antibody like the rabbit recombinant [EPR10062] offers advantages . For applications requiring higher sensitivity or detection of potentially modified forms of the protein, polyclonal antibodies may be preferred .

For techniques like Western blotting, both antibody types are suitable, with recommended dilutions typically ranging from 1:500 to 1:1000 for polyclonal antibodies . For immunohistochemistry, polyclonal antibodies are often used at 1:50 to 1:200 dilutions, while immunofluorescence applications generally employ dilutions of 1:100 to 1:500 .

Always validate antibody performance in your specific experimental system before proceeding with full-scale experiments.

What tissue and subcellular localization patterns are expected when using TSEN54 antibodies?

When performing immunohistochemistry or immunofluorescence with TSEN54 antibodies, researchers should expect predominant nuclear staining patterns. Variations in staining intensity may correlate with tissue-specific expression levels or disease states. While the search results don't provide specific tissue expression patterns, researchers studying neurological tissues may observe particular relevance given TSEN54's association with pontocerebellar hypoplasia .

For immunofluorescence studies, co-staining with nuclear markers can help confirm the expected subcellular localization. Any unexpected localization patterns should be validated with multiple antibodies and complementary techniques.

What positive and negative controls should be included when working with TSEN54 antibodies?

Proper experimental controls are essential for validating TSEN54 antibody specificity:

Positive Controls:

• Cell lines known to express TSEN54 (specific human cell lines not mentioned in search results, but cells of neural origin may be appropriate given TSEN54's role in neurological disorders)

• Recombinant TSEN54 protein (for Western blotting)

• Tissues with documented TSEN54 expression

Negative Controls:

• Isotype control antibodies matched to the TSEN54 antibody's host species and isotype

• Antibody pre-incubated with immunizing peptide (peptide competition assay) to confirm specificity

• TSEN54 knockdown or knockout cells (if available)

• Secondary antibody-only controls to assess non-specific binding

Including these controls helps distinguish specific from non-specific signals and validates antibody performance in your experimental system .

How can TSEN54 antibodies be used to investigate its role in pontocerebellar hypoplasia?

Mutations in TSEN54 have been implicated in pontocerebellar hypoplasia type 2 (PCH2), a neurodegenerative disorder characterized by cerebellar hypoplasia, progressive microcephaly, and severe developmental delay . TSEN54 antibodies can be invaluable tools for investigating the molecular mechanisms underlying this pathology.

Researchers can employ TSEN54 antibodies to:

• Compare TSEN54 protein expression levels in patient-derived samples versus healthy controls using Western blotting

• Examine TSEN54 localization in brain tissue samples using immunohistochemistry to identify potential mislocalization in disease states

• Investigate TSEN54 interaction partners in normal versus disease states using co-immunoprecipitation followed by mass spectrometry

• Assess the impact of specific TSEN54 mutations on protein stability and localization using cell models expressing mutant TSEN54 variants

When investigating disease mechanisms, it's crucial to select antibodies that can recognize both wild-type and mutant forms of TSEN54, unless the mutation affects the epitope recognized by the antibody.

What approaches can be used to study TSEN54's interaction with the tRNA splicing complex and pre-mRNA processing machinery?

TSEN54 functions within multiprotein complexes involved in both tRNA splicing and pre-mRNA processing . To investigate these interactions, researchers can employ several advanced approaches:

• Co-immunoprecipitation (Co-IP): Use TSEN54 antibodies to pull down the protein along with its interaction partners, followed by Western blotting or mass spectrometry to identify associated proteins.

• Proximity Ligation Assay (PLA): This technique allows visualization of protein-protein interactions in situ, providing spatial information about where TSEN54 interacts with other complex components.

• Chromatin Immunoprecipitation (ChIP): If TSEN54 associates with chromatin during transcription-coupled RNA processing, ChIP using TSEN54 antibodies can identify genomic regions where it operates.

• Immunofluorescence co-localization: Dual staining with TSEN54 antibodies and antibodies against other complex components can reveal their spatial relationship in cells.

• Cross-linking followed by immunoprecipitation: This approach can capture transient interactions that might be missed by standard Co-IP.

When designing these experiments, researchers should consider potential epitope masking when TSEN54 is engaged in protein complexes, which might affect antibody binding.

How can I investigate TSEN54's role in RNA processing pathways beyond tRNA splicing?

Evidence suggests TSEN54 participates in mRNA processing through its association with pre-mRNA 3'-end processing factors . To explore these extended functions, researchers can employ several strategies using TSEN54 antibodies:

• RNA Immunoprecipitation (RIP): Use TSEN54 antibodies to immunoprecipitate RNA-protein complexes, followed by RNA sequencing to identify RNA species associated with TSEN54 beyond pre-tRNAs.

• CLIP-seq (Cross-linking immunoprecipitation followed by sequencing): This technique can identify direct RNA binding sites of TSEN54, providing insight into its RNA substrate specificity.

• Immunodepletion experiments: Deplete TSEN54 from nuclear extracts using specific antibodies and assess the impact on various RNA processing reactions in vitro.

• Proximity-dependent biotin identification (BioID): Fuse TSEN54 to a biotin ligase and identify proteins in its vicinity, potentially revealing connections to various RNA processing machineries.

• Differential gene expression analysis: Compare RNA-seq data from TSEN54-depleted versus control cells to identify RNA species whose processing depends on TSEN54.

These approaches can uncover novel functions of TSEN54 in RNA metabolism beyond its established role in tRNA splicing.

What are the optimal protocols for Western blotting using TSEN54 antibodies?

For effective Western blotting detection of TSEN54, consider the following protocol optimizations:

• Sample preparation:

  • Cellular fractionation may be beneficial as TSEN54 is primarily nuclear

  • Use phosphatase inhibitors in lysis buffers to preserve potential phosphorylation states

  • Standard RIPA or NP-40 buffers are typically suitable

• Gel electrophoresis:

  • Human TSEN54 has a molecular weight of approximately 58 kDa

  • 10% SDS-PAGE gels are appropriate for resolution

• Antibody conditions:

  • For polyclonal antibodies, recommended dilutions range from 1:500 to 1:1000

  • Primary antibody incubation overnight at 4°C typically yields optimal results

  • For recombinant monoclonal antibodies, follow manufacturer's recommendations

• Detection:

  • Both chemiluminescence and fluorescence-based detection methods are suitable

  • Signal enhancement systems may be needed for low abundance detection

• Controls:

  • Include positive controls (cell lines known to express TSEN54)

  • Consider peptide competition controls to verify specificity

Note that post-translational modifications or splice variants may result in unexpected molecular weight shifts, which should be documented and interpreted carefully.

What considerations are important for immunohistochemistry and immunofluorescence with TSEN54 antibodies?

When performing immunohistochemistry (IHC) or immunofluorescence (IF) with TSEN54 antibodies, consider these methodological factors:

• Fixation methods:

  • Paraformaldehyde (4%) is typically suitable for TSEN54 detection

  • Methanol fixation may better preserve nuclear antigens

  • Test multiple fixation protocols if initial results are suboptimal

• Antigen retrieval:

  • Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) is often effective

  • Enzymatic retrieval methods may be alternatives if HIER yields poor results

• Antibody dilutions:

  • For IHC: 1:50 to 1:200 dilutions are recommended for polyclonal antibodies

  • For IF: 1:100 to 1:500 dilutions are typically effective

• Blocking conditions:

  • Use serum from the species in which the secondary antibody was raised

  • BSA (3-5%) can reduce background in combination with serum

• Signal detection:

  • For IHC: DAB or AEC chromogens are suitable

  • For IF: Alexa Fluor conjugates provide good signal-to-noise ratio

  • Nuclear counterstains (DAPI, Hoechst) help confirm nuclear localization

• Controls:

  • Include no-primary-antibody controls

  • Use tissues or cells with known TSEN54 expression patterns

Given TSEN54's nuclear localization, careful attention to nuclear membrane permeabilization is essential for optimal antibody access to the target.

How can I validate the specificity of a TSEN54 antibody for my experimental system?

Thorough validation of TSEN54 antibodies is crucial before proceeding with experimental applications. Consider these validation approaches:

• Western blot analysis:

  • Confirm a single band of expected molecular weight (~58 kDa for human TSEN54)

  • Compare multiple TSEN54 antibodies recognizing different epitopes

  • Perform peptide competition assays to verify specificity

• Genetic approaches:

  • Use TSEN54 knockdown/knockout systems and verify reduced/absent signal

  • Overexpress tagged TSEN54 and confirm co-localization with antibody staining

• Cross-reactivity testing:

  • If working with animal models, confirm cross-reactivity with the species of interest

  • Test antibody on tissues/cells known to lack TSEN54 expression as negative controls

• Multiple application validation:

  • Confirm consistent results across different applications (WB, IHC, IF)

  • Discrepancies between applications may indicate context-dependent epitope accessibility

• Mass spectrometry validation:

  • Perform immunoprecipitation followed by mass spectrometry to confirm the identity of the precipitated protein

Remember that different lots of the same antibody may show variation in performance, particularly for polyclonal antibodies, necessitating validation for each new lot.

What are common challenges in TSEN54 antibody experiments and how can they be resolved?

Researchers working with TSEN54 antibodies may encounter several technical challenges:

• Weak or absent signal:

  • Potential solutions: Increase antibody concentration, optimize antigen retrieval, extend incubation time, try alternative fixation methods, or use signal amplification systems

  • Consider nuclear extraction protocols to enrich for TSEN54 if detecting by Western blot

• High background:

  • Potential solutions: More stringent blocking conditions, reduce primary antibody concentration, increase wash duration/stringency, use monoclonal antibodies if specificity is an issue

  • Pre-adsorb antibodies against tissues from knockout models if available

• Multiple bands in Western blot:

  • Potential causes: Splice variants, proteolytic degradation, post-translational modifications

  • Solutions: Use fresh samples with protease inhibitors, compare with recombinant protein standard, perform peptide competition

• Inconsistent results between experiments:

  • Maintain detailed protocols and standardize critical parameters like incubation times and temperatures

  • Consider antibody batch variation, especially for polyclonal antibodies

  • Freeze-thaw cycles may affect antibody performance; aliquot upon receipt

• Discrepancies between different techniques:

  • Some epitopes may be masked in certain experimental conditions

  • Try antibodies targeting different epitopes of TSEN54

Thorough documentation of experimental conditions facilitates troubleshooting and enables reproduction of successful protocols.

How should I interpret TSEN54 localization patterns in different cell types and under various experimental conditions?

Interpreting TSEN54 localization requires consideration of its biological functions and potential regulatory mechanisms:

Changes in TSEN54 localization may have functional significance related to its roles in RNA processing or potentially uncharacterized functions.

What experimental approaches can resolve contradictory findings on TSEN54 expression or function?

When faced with contradictory findings regarding TSEN54, consider these approaches to resolve discrepancies:

• Antibody-independent methods:

  • Implement RNA-level detection (qRT-PCR, RNA-seq) to complement protein-level analyses

  • Use CRISPR/Cas9 to tag endogenous TSEN54 with fluorescent proteins or epitope tags

  • Deploy mass spectrometry-based proteomics for unbiased identification

• Multiple antibody approach:

  • Use several antibodies targeting different TSEN54 epitopes

  • Compare monoclonal and polyclonal antibodies results

  • Thoroughly document each antibody's validation status

• Genetic manipulation:

  • Employ RNAi or CRISPR-based approaches to manipulate TSEN54 levels

  • Rescue experiments with wild-type TSEN54 can confirm specificity of observed phenotypes

• Contextual considerations:

  • Evaluate cell type-specific differences in TSEN54 expression or function

  • Consider developmental stage, disease state, or stress conditions as sources of variation

  • Assess the influence of experimental conditions (serum starvation, confluency, etc.)

• Collaborative validation:

  • Engage with other laboratories to independently replicate key findings

  • Consider different technical approaches to address the same biological question

Documenting all relevant experimental details facilitates identification of variables that might explain contradictory results.

What emerging research areas might benefit from TSEN54 antibody applications?

TSEN54 research has several promising frontiers where specific antibodies will be valuable tools:

• Neurodevelopmental disorders: Given TSEN54's association with pontocerebellar hypoplasia, antibodies will be crucial for studying its expression patterns during brain development and in patient-derived samples .

• RNA processing networks: As our understanding of coordinated RNA processing pathways expands, TSEN54 antibodies can help map physical and functional interactions between tRNA processing and other RNA metabolism pathways.

• Stress response mechanisms: RNA processing factors often participate in stress responses; TSEN54 antibodies could reveal potential roles in cellular adaptation to environmental challenges.

• Single-cell applications: Adapting TSEN54 antibodies for single-cell proteomics or high-resolution imaging could reveal cell-to-cell variability in expression or localization.

• Therapeutic target validation: If TSEN54 emerges as a potential therapeutic target, antibodies will be essential for target engagement studies and mechanism-of-action investigations.

These research directions will benefit from continued refinement of TSEN54 antibodies and development of new tools for studying its biology.

What methodological advances might improve TSEN54 detection in future research?

Several technological advances may enhance TSEN54 research capabilities:

• Single-molecule detection: Super-resolution microscopy combined with highly specific antibodies could reveal TSEN54 distribution at nanometer resolution.

• Proximity labeling: Antibody-enzyme conjugates that label proteins in proximity to TSEN54 could map its immediate interaction neighborhood in different cellular contexts.

• Conformational-specific antibodies: Developing antibodies that recognize specific TSEN54 conformational states could provide insights into its activation mechanisms.

• Multiplexed detection systems: Methods allowing simultaneous detection of TSEN54 alongside dozens of other proteins could position it within complex cellular networks.

• In vivo imaging: Development of antibody fragments suitable for in vivo imaging could enable visualization of TSEN54 dynamics in living systems.

• Quantitative standards: Creating reference standards for absolute quantification would enable more precise measurement of TSEN54 across different experimental systems.